Corixa Corp. 's recent deal with Johnson & Johnson subsidiary Ortho-Clinical Diagnostics Inc. brings Ortho exclusive worldwide diagnostics rights to Corixa's breast cancer genes and antigens. It also illustrates how biotech companies caught up in long-term programs for therapeutics can capture some near-term value. While Corixa's lead drug, tositumomab/iodine I-131 tositumomab (Bexxar) is delayed at the FDA, the deal gives the company a source of revenues that may be small but is at least real.
The deal revolves around a series of breast cancer genes, which Corixa has identified and characterized. Ortho's Advanced Diagnostic and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?